VELNEX-XR

Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI). Its mechanism of action involves: Inhibition of serotonin (5-HT) reuptake – Increases serotonin levels in the synaptic cleft, enhancing mood regulation. Inhibition of norepinephrine (NE) reuptake – Boosts norepinephrine levels, improving alertness and energy. Weak dopamine (DA) reuptake inhibition – At higher doses, venlafaxine slightly affects dopamine reuptake, contributing to its therapeutic effects.

Absorption Absorption: 92% Bioavailability: 45% Peak plasma time: 2-3 hr (immediate release); 5.5-9 hr (extended release) Concentration: Immediate release, 225-290 ng/mL; extended release, 150-260 ng/mL Distribution Protein bound: 27-30% Vd: Immediate release, 7.5 L/kg Metabolism Metabolized in liver by CYP2D6 Metabolites: O-desmethylvenlafaxine Enzymes inhibited: CYP2D6 (weak) Elimination Half-life: 5-11 hr (prolonged in renal or hepatic dysfunction) Dialyzable: No Excretion: Urine (87%)

Depression and Anxiety: 75 mg given once daily. Patients not responding to the initial 75 mg/day dose may benefit from dose increases up to a maximum dose of 375 mg/day. Dosage increases can be made at intervals of 2 weeks or more. --- Panic Disorder: 37.5 mg/day of prolonged-release venlafaxine be used for 7 days. Dosage should then be increased to 75 mg/day. Patients not responding to the 75 mg/day dose may benefit from dose increases up to a maximum dose of 225 mg/day.

VELNEX-SR is available as blister strip of 10*10s.